Cont A1

binds to the amyloid deposit or a component thereof to the patient, wherein the antibody specifically binds to an epitope within residues 13-28 of Aβ.

57. The method of claim 56, wherein the antibody is the monoclonal antibody designated as 266.

58. The method of claim 56, wherein the antibody competes with the monoclonal antibody designated as 266 for binding to Aβ.

59. The method of claim 56, wherein the disease is Alzheimer's disease.

60. The method of claim 56, wherein the amyloid deposit comprises aggregated Aβ peptide.

61. The method of claim 56, wherein the patient is a human.

62. The method of claim 56, wherein the patient is asymptomatic.

63. The method of claim 56, wherein the patient is under 50.

64. The method of claim 56, wherein the patient has inherited risk factors indicating susceptibility to Alzheimer's disease.

65. The method of claim 56, wherein the patient has no known risk factors for Alzheimer's disease.

66. The method of claim 56, wherein the antibody is a fragment of an intact antibody that competes with the intact antibody for specific binding to Aβ, and the antibody fragment is selected from the group consisting of Fab, Fab', $F(ab')_2$, Fabc, and Fv.

67. The method of claim 56, wherein the antibody is a human antibody.

68. The method of claim 66, wherein the human antibody is an antibody fragment.

69. The method of claim 67, wherein the human antibody is produced by recombinant expression.

70. The method of claim 66, wherein the antibody is a human antibody.

71. The method of claim 56, wherein the antibody is a humanized antibody.

72. The method of claim 71, wherein the humanized antibody is an antibody fragment.

73. The method of claim 66, wherein the antibody is a humanized antibody.

74. The method of claim 56, wherein the antibody is a chimeric antibody.

75. The method of claim 74, wherein the chimeric antibody is an antibody fragment.

76. The method of claim 66, wherein the antibody is a chimeric antibody.

77. The method of claim 56, wherein the antibody is a bispecific antibody.

78. The method of claim 77, wherein the bispecific antibody is an antibody fragment.

79. The method of claim 66, wherein the antibody is a bispecific antibody.

80. The method of claim 56, wherein the antibody is a mouse antibody.

81. The method of claim 56, wherein the antibody is a polyclonal antibody.

82. The method of claim 56, wherein the antibody is a monoclonal antibody.

83. The method of claim 81, wherein the antibody is a rabbit antibody.

84. The method of claim 56, further comprising administering an effective dosage of a second antibody that binds to the amyloid deposit or a component thereof.

85. The method of claim 82, wherein the isotype of the antibody is IgG1.

86. The method of claim 56, wherein a chain of the antibody is fused to a heterologous polypeptide.

87. The method of claim 56, wherein the dosage of antibody is at least 1 mg/kg body weight of the patient.

88. The method of claim 56, wherein the dosage of antibody is at least 10 mg/kg body weight of the patient.

89. The method of claim 56, wherein the antibody is administered with a carrier as a pharmaceutical composition.

90. The method of claim 56, wherein the antibody is a human antibody to Aβ prepared from B cells from a human immunized with an Aβ peptide.

91. The method of claim 90, wherein the human immunized with Aβ peptide is the patient.